Portland, OR -- (SBWIRE) -- 10/06/2017 -- A recent report published by Progressive Markets on the energy and power sector, which titled, "Global Bipolar Disorder Market - Size, Trend, Share, Opportunity Analysis & Forecast, 2014-2025", the industry is expected to register a CAGR of 3.2% during the period, 2017–2025. It is suitable for manufacturers and stakeholders owing to comprehensive analysis it offers of factors that increase or decrease growth of the market.

Based on drug classes, the study segments the global bipolar disorder market into mood stabilizers, atypical antipsychotics, anticonvulsants, anti-anxiety drugs, and antidepressant drugs. According to it, the industry includes certain mechanism of actions, such as selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, beta blockers, and benzodiazepines. Geographically, it segments the market into Europe, North America, Latin America Middle East & Africa (LAMEA), and Asia-Pacific. The research analyzes share of the industry by drug classes, mechanism of actions, and geographies during the period, 2014–2025. It assesses market size of each drug class and mechanism of action by region for the historic period and forecast period, 2014–2016 and 2017–2025, respectively. In addition, it evaluates market size of all countries of the industry during historic period and forecast period.

The analysts describe features that cause slow progress of the global bipolar disorder market, such as unapproved drugs for disorder and strict regulations. Moreover, the study offers key takeaways of the industry, such as it provides great competitive edge to manufacturers, stakeholders, and new entrants. It provides comprehensive evaluation of aspects that have potential to restrict or drive the industry.

Get PDF Brochure of this Report: https://www.progressivemarkets.com/request-sample/bipolar-disorder-market

The research gives a brief introduction of the global bipolar disorder market in terms of its scope. It offers summary which includes significant findings, market attractiveness, competitive landscape, recent developments, and trend analysis. It incorporates research methodology, such as Porter's Five Forces Analysis (PFFA) to understand rivalry in the industry. This also includes bargaining power of the supplier & buyer and threat from substitutes & new entrepreneurs. It divides the industry into drug classes, mechanisms, and geographies.

The study discusses big market players of the global bipolar disorder market, such as Otsuka, Ferrer, Pfizer, Janssen pharmaceuticals, Abbott Laboratories Inc., Allergan, Bristol-Myers Squibb Company, Eli Lilly and Company, AstraZeneca PLC, Cephalon Inc., Dainippon Sumitomo Pharma Co. Ltd., GlaxoSmithKline PLC, Forest Laboratories Inc., Gedeon Richter PLC, Merck & Co., Inc., H. Lundbeck A/S, and others. It offers brief introduction of every manufacturer. Further, it analyzes business and finance segment of each company. It also evaluates recent advancements made by every firm. The experts describe various factors that vendors adopt to evolve market trends. These include product development, acquisition, product approval, and collaboration. The report explores factors that accelerate growth of the industry which include advancement in technology. It discusses alternate aspects that propel demand of the industry, such as increase in number of bipolar diseases.

Get Customized Report: https://www.progressivemarkets.com/request-customization/bipolar-disorder-market